MEP43208A - Beta-amyloid-analogue-t-cell epitop vaccine - Google Patents
Beta-amyloid-analogue-t-cell epitop vaccineInfo
- Publication number
- MEP43208A MEP43208A MEP-432/08A MEP43208A MEP43208A ME P43208 A MEP43208 A ME P43208A ME P43208 A MEP43208 A ME P43208A ME P43208 A MEP43208 A ME P43208A
- Authority
- ME
- Montenegro
- Prior art keywords
- amyloid
- methods
- app
- analogs
- vaccination
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 5
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 abstract 4
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 abstract 4
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 abstract 4
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 4
- 238000002255 vaccination Methods 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000002649 immunization Methods 0.000 abstract 2
- 230000003053 immunization Effects 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 abstract 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 abstract 1
- 230000007082 Aβ accumulation Effects 0.000 abstract 1
- 230000003942 amyloidogenic effect Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200101231 | 2001-08-20 | ||
| US33754301P | 2001-10-22 | 2001-10-22 | |
| US37302702P | 2002-04-16 | 2002-04-16 | |
| DKPA200200558 | 2002-04-16 | ||
| PCT/DK2002/000547 WO2003015812A2 (fr) | 2001-08-20 | 2002-08-20 | Nouvelle methode de regulation negative d'amyloide |
| YU13304A RS51699B (sr) | 2001-08-20 | 2002-08-20 | Beta-amiloid-analog-t-ćelijski-epitop vakcina |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MEP43208A true MEP43208A (en) | 2011-02-10 |
Family
ID=32870659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-432/08A MEP43208A (en) | 2001-08-20 | 2002-08-20 | Beta-amyloid-analogue-t-cell epitop vaccine |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US20030157117A1 (fr) |
| EP (3) | EP1685847A1 (fr) |
| JP (2) | JP2004538332A (fr) |
| KR (3) | KR20100086520A (fr) |
| CN (1) | CN101675992B (fr) |
| AR (1) | AR036270A1 (fr) |
| AT (1) | ATE334698T1 (fr) |
| AU (3) | AU2002325199B2 (fr) |
| BR (1) | BR0212047A (fr) |
| CA (1) | CA2457140C (fr) |
| CO (1) | CO5560581A2 (fr) |
| CY (1) | CY1105737T1 (fr) |
| DE (1) | DE60213615T3 (fr) |
| DK (1) | DK1420815T3 (fr) |
| EA (2) | EA007533B1 (fr) |
| ES (1) | ES2269749T5 (fr) |
| HK (1) | HK1064934A1 (fr) |
| HR (2) | HRP20040218A2 (fr) |
| HU (1) | HUP0400669A3 (fr) |
| IL (2) | IL159964A0 (fr) |
| IS (1) | IS7133A (fr) |
| ME (1) | MEP43208A (fr) |
| MX (1) | MXPA04001467A (fr) |
| MY (1) | MY144532A (fr) |
| NZ (2) | NZ547224A (fr) |
| PL (1) | PL215125B1 (fr) |
| PT (1) | PT1420815E (fr) |
| RS (1) | RS51699B (fr) |
| SI (1) | SI1420815T1 (fr) |
| WO (1) | WO2003015812A2 (fr) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080017471A (ko) * | 2000-02-21 | 2008-02-26 | 파멕사 에이/에스 | 아밀로이드의 하향-조절을 위한 신규한 방법 |
| DE60114157T2 (de) * | 2000-02-21 | 2006-06-29 | Pharmexa A/S | Verfahren zur herabregulierung von amyloid |
| US7320793B2 (en) | 2001-01-19 | 2008-01-22 | Cytos Biotechnology Ag | Molecular antigen array |
| MY144532A (en) * | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
| US9034337B2 (en) * | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
| US8697082B2 (en) * | 2002-11-01 | 2014-04-15 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| TW200509968A (en) * | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| US8506959B2 (en) * | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| US20080014194A1 (en) * | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| KR100546066B1 (ko) * | 2003-03-21 | 2006-01-26 | 한국생명공학연구원 | 베타아밀로이드 유전자의 다중 연결체를 발현하는 형질전환 식물 세포 및 이로부터 배양된 식물 |
| US7358331B2 (en) * | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| US7807171B2 (en) | 2003-07-25 | 2010-10-05 | Ac Immune Sa | Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers |
| EP1687333A2 (fr) * | 2003-10-30 | 2006-08-09 | Pharmexa A/S | Procede de regulation negative du facteur de croissance endotheliale vasculaire |
| WO2005047860A2 (fr) | 2003-11-08 | 2005-05-26 | Elan Pharmaceuticals, Inc. | Anticorps a l'alpha-synucleine |
| JP2007522119A (ja) * | 2004-01-28 | 2007-08-09 | キュリックス エーピーエス | アミロイド関連疾患用ワクチンとしてのアミロイドタンパク質のコンジュゲート |
| KR100639397B1 (ko) * | 2004-03-18 | 2006-10-26 | (주)에스제이바이오메드 | 항비만용 면역원성 하이브리드 폴리펩타이드 및 이를포함하는 항비만 백신 조성물 |
| GB0424563D0 (en) | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
| ATE535252T1 (de) * | 2005-05-05 | 2011-12-15 | Merck Sharp & Dohme | Peptid-konjugat-zusammensetzungen und -verfahren zur prävention und behandlung von alzheimer- krankheit |
| CA2631195C (fr) | 2005-11-30 | 2016-04-05 | Abbott Laboratories | Anticorps monoclonaux et utilisation de ceux-ci |
| CN101432302A (zh) | 2005-11-30 | 2009-05-13 | 艾博特公司 | 抗－Aβ球聚体抗体，其抗原结合部分，相应的杂交瘤、核酸、载体、宿主细胞，生产所述抗体的方法，包含所述抗体的组合物，所述抗体的应用以及使用所述抗体的方法 |
| CN101421299A (zh) * | 2006-02-22 | 2009-04-29 | 株式会社林原生物化学研究所 | 用于诱导产生抗淀粉样β肽抗体的肽疫苗 |
| US8188046B2 (en) | 2006-10-16 | 2012-05-29 | University Of South Florida | Amyloid beta peptides and methods of use |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| EP2118300B1 (fr) * | 2007-02-23 | 2015-05-27 | Prothena Biosciences Limited | Prévention et traitement de maladies synucléinopathiques et amyloïdogéniques |
| US8147833B2 (en) * | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| EP2124952A2 (fr) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Méthode de traitement d'amyloïdoses |
| WO2008106657A2 (fr) | 2007-03-01 | 2008-09-04 | Intezyne Technologies, Inc. | Peptides bêta-amyloïde encapsulés |
| WO2008124646A2 (fr) * | 2007-04-06 | 2008-10-16 | The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services | Utilisation de protéines amyloïdes en tant qu'échafaudages pour des vaccins |
| TR201802286T4 (tr) | 2007-04-20 | 2018-03-21 | The Chemo Sero Therapeutic Res Institute | Peptidle bağışıklık yanıtının arttırılması için yöntem. |
| WO2010005858A1 (fr) * | 2008-07-08 | 2010-01-14 | Merck & Co., Inc. | Vaccin pour le traitement de la maladie d’alzheimer |
| WO2010044464A1 (fr) * | 2008-10-16 | 2010-04-22 | 財団法人化学及血清療法研究所 | Peptide amyloïde bêta modifié |
| US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| US9289488B2 (en) | 2010-08-12 | 2016-03-22 | Ac Immune Sa | Vaccine engineering |
| MX358739B (es) | 2010-08-14 | 2018-09-03 | Abbvie Inc Star | Proteinas de union a amiloide beta. |
| TW201223561A (en) | 2010-10-26 | 2012-06-16 | Ac Immune Sa | Preparation of an antigenic construct |
| US20120328605A1 (en) * | 2010-10-27 | 2012-12-27 | Daniel Larocque | Compositions and uses |
| CA2885924C (fr) | 2012-08-21 | 2022-12-13 | Institute For Molecular Medicine, Inc. | Compositions et methodes liees a des maladies associees aux depots d'amyloide, de proteine tau et d'alpha-synucleine |
| WO2015017280A1 (fr) | 2013-07-28 | 2015-02-05 | Qantu Therapeutics, Inc. | Formulation de vaccins induisant une réponse immunitaire de type th2 |
| CN106163540A (zh) * | 2013-09-13 | 2016-11-23 | 安达卢西亚进步与健康公共基金会 | 用于治疗蛋白病或构象病的聚集蛋白和分子伴侣的组合 |
| CA2941416C (fr) | 2014-03-11 | 2022-10-18 | Universite D'aix-Marseille | Peptide chimere interagissant avec les gangliosides des membranes cellulaires |
| JP2018508481A (ja) * | 2015-02-02 | 2018-03-29 | ザ ユニバーシティ オブ バーミンガム | 複数のｔ細胞エピトープを有する標的化部分ペプチドエピトープ複合体 |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| CN104880441B (zh) * | 2015-05-14 | 2017-12-22 | 上海皓拓生物技术有限公司 | β‑分泌酶特异性抑制剂的筛选方法及其筛选系统 |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| MA46611B1 (fr) | 2016-10-28 | 2020-08-31 | H Lundbeck As | Traitements combinés comprenant des imidazopyrazinones pour le traitement de troubles psychiatriques et/ou cognitifs |
| CA3041595A1 (fr) | 2016-10-28 | 2018-05-03 | H. Lundbeck A/S | Traitements combines comprenant l'administration d'imidazopyrazinones |
| WO2018132768A1 (fr) * | 2017-01-13 | 2018-07-19 | Sanna Pietro P | Procédés et compositions pour le traitement de l'hyperactivité hpa |
| CN108295252B (zh) * | 2017-05-25 | 2020-05-01 | 成都安特金生物技术有限公司 | 一种制备狂犬病结合疫苗的方法 |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| LT3723807T (lt) | 2017-12-14 | 2021-12-10 | H. Lundbeck A/S | Kombinuoti gydymai, apimantys 1h-pirazolo[4,3-b]piridinų vartojimą |
| CN117447475A (zh) | 2017-12-20 | 2024-01-26 | H.隆德贝克有限公司 | 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶 |
| CN112165956A (zh) * | 2018-04-10 | 2021-01-01 | Ac免疫有限公司 | 抗Aβ治疗性疫苗 |
| CA3095983A1 (fr) | 2018-04-10 | 2019-10-17 | Ac Immune Sa | Vaccins therapeutiques anti-abeta |
| EP3952913A4 (fr) * | 2019-04-12 | 2023-05-10 | The Johns Hopkins University | Cellules présentant l'antigène artificielles tolérogéniques |
| GB202008250D0 (en) * | 2020-06-02 | 2020-07-15 | Emergex Vaccines Holding Ltd | Diagnosis, prevention and treatment of coronavirus infection |
| CN115925987A (zh) * | 2022-02-28 | 2023-04-07 | 安域生物科技(杭州)有限公司 | 基于β-淀粉样蛋白修饰的抗原多肽及其应用 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| US4596792A (en) | 1981-09-04 | 1986-06-24 | The Regents Of The University Of California | Safe vaccine for hepatitis containing polymerized serum albumin |
| JPS5938877A (ja) | 1982-08-30 | 1984-03-02 | Musashi Eng Kk | 紙葉判別方法 |
| US4599231A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4599230A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4608251A (en) | 1984-11-09 | 1986-08-26 | Pitman-Moore, Inc. | LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues |
| US4601903A (en) | 1985-05-01 | 1986-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease |
| US5223482A (en) * | 1986-11-17 | 1993-06-29 | Scios Nova Inc. | Recombinant Alzheimer's protease inhibitory amyloid protein and method of use |
| US5278056A (en) * | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
| US5192688A (en) * | 1988-08-15 | 1993-03-09 | Switzer Iii Robert C | Histological analysis method |
| US5753624A (en) * | 1990-04-27 | 1998-05-19 | Milkhaus Laboratory, Inc. | Materials and methods for treatment of plaquing disease |
| US5200339A (en) * | 1990-08-17 | 1993-04-06 | Abraham Carmela R | Proteases causing abnormal degradation of amyloid β-protein precursor |
| US5780587A (en) * | 1990-08-24 | 1998-07-14 | President And Fellows Of Harvard College | Compounds and methods for inhibiting β-protein filament formation and neurotoxicity |
| US5780036A (en) * | 1991-08-26 | 1998-07-14 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus |
| ATE245446T1 (de) | 1992-02-11 | 2003-08-15 | Jackson H M Found Military Med | Dualer träger für immunogene konstrukte |
| AU678152B2 (en) | 1992-03-27 | 1997-05-22 | Whitehead Institute For Biomedical Research | Non-infectious HIV particles and uses therefor |
| US5851787A (en) | 1992-04-20 | 1998-12-22 | The General Hospital Corporation | Nucleic acid encoding amyloid precursor-like protein and uses thereof |
| WO1993023076A1 (fr) | 1992-05-20 | 1993-11-25 | The Johns-Hopkins University | Therapie utilisant des recepteurs de substitution |
| DK100592D0 (da) | 1992-08-10 | 1992-08-10 | Mouritsen & Elsner Aps | Metode til kemisk kobling paa faste faser |
| US5958883A (en) * | 1992-09-23 | 1999-09-28 | Board Of Regents Of The University Of Washington Office Of Technology | Animal models of human amyloidoses |
| US5747323A (en) * | 1992-12-31 | 1998-05-05 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Retroviral vectors comprising a VL30-derived psi region |
| DK96493D0 (da) | 1993-08-26 | 1993-08-26 | Mouritsen Og Elsner Aps | Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden |
| AU707083B2 (en) | 1993-08-26 | 1999-07-01 | Bavarian Nordic Inc. | Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes |
| WO1995007707A1 (fr) | 1993-09-14 | 1995-03-23 | Cytel Corporation | Alteration de la reponse immunitaire a l'aide de peptides se liant a des alleles pan dr |
| AUPM411994A0 (en) | 1994-02-25 | 1994-03-24 | Deakin Research Limited | Epitopes |
| US5709995A (en) * | 1994-03-17 | 1998-01-20 | The Scripps Research Institute | Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses |
| US5573916A (en) * | 1994-05-19 | 1996-11-12 | Coretech, Inc. | Immunogenic constructs comprising b-cell and t-cell epitopes on common carrier |
| IL115743A0 (en) | 1994-10-28 | 1996-01-19 | American Nat Red Cross | A mammal with cells containing a transgene and its production |
| US5589154A (en) * | 1994-11-22 | 1996-12-31 | Rutgers, The State University Of New Jersey | Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease |
| US5854204A (en) * | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals, Inc. | Aβ peptides that modulate β-amyloid aggregation |
| AU721954B2 (en) | 1995-06-07 | 2000-07-20 | Connaught Laboratories Inc. | Expression of lipoproteins |
| US5874469A (en) | 1996-01-05 | 1999-02-23 | Alcon Laboratories, Inc. | Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs |
| US5985581A (en) | 1996-07-25 | 1999-11-16 | The Mclean Hospital Corporation | Use of presenilin-1 for diagnosis of alzheimers disease |
| AUPO390396A0 (en) | 1996-11-29 | 1996-12-19 | Csl Limited | Novel promiscuous T helper cell epitopes |
| EP1005374B1 (fr) | 1997-01-22 | 2007-04-18 | Zycos Inc. | Microparticules pour l'administration de l'acide nucleique |
| WO1999024468A1 (fr) | 1997-11-11 | 1999-05-20 | The Board Of Regents Of The University Of Oklahoma | Facteur toxique d'origine endotheliale lie a la maladie d'alzheimer et ses methodes d'utilisation |
| US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6787523B1 (en) * | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US6761888B1 (en) * | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US6913745B1 (en) * | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
| US20040062802A1 (en) * | 1998-04-02 | 2004-04-01 | Hermelin Victor M. | Maximizing effectiveness of substances used to improve health and well being |
| NO314086B1 (no) * | 1998-05-08 | 2003-01-27 | Gemvax As | Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til |
| NZ509917A (en) | 1998-07-21 | 2003-05-30 | Pharmexa As | Coating of solid surfaces with activated polyhydroxypolymers |
| IL141588A0 (en) * | 1998-09-15 | 2002-03-10 | M & E Biotech As | Method for down-regulating osteoprotegerin ligand activity |
| EA003634B1 (ru) | 1998-10-05 | 2003-08-28 | Фармэкса А/С | Новые способы терапевтической вакцинации |
| GB2361948B (en) † | 1998-11-06 | 2003-04-16 | Baker Hughes Inc | Drilling fluid systems with improved fluid loss properties |
| WO2000040741A2 (fr) | 1999-01-07 | 2000-07-13 | The Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services, The National Institutes Of Health | Systeme de vecteurs lentiviraux |
| IL145982A0 (en) * | 1999-04-19 | 2002-07-25 | Smithkline Beecham Biolog | Vaccines |
| US6787637B1 (en) * | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
| PE20010212A1 (es) | 1999-06-01 | 2001-02-22 | Neuralab Ltd | Composiciones del peptido a-beta y procesos para producir las mismas |
| CA2388559A1 (fr) | 1999-11-29 | 2001-06-07 | Neurochem Inc. | Vaccin destine a la prevention et au traitement de la maladie d'alzheimer et d'autres maladies associees aux substances amyloides |
| EP1237930B1 (fr) * | 1999-12-08 | 2006-11-08 | Intellect Neurosciences, Inc. | Peptides amyloides beta chimeriques |
| DE60114157T2 (de) * | 2000-02-21 | 2006-06-29 | Pharmexa A/S | Verfahren zur herabregulierung von amyloid |
| KR20080017471A (ko) * | 2000-02-21 | 2008-02-26 | 파멕사 에이/에스 | 아밀로이드의 하향-조절을 위한 신규한 방법 |
| GB0004530D0 (en) | 2000-02-25 | 2000-04-19 | Univ Nottingham | Adjuvants |
| WO2001090182A2 (fr) * | 2000-05-22 | 2001-11-29 | New York University | Peptides immunogenes synthetiques mais non-amyloidogenes homologues de beta-amyloide, destines a induire une reaction immunitaire contre les peptides beta-amyloide et les depots amyloides |
| PL366031A1 (en) | 2000-11-10 | 2005-01-24 | Wyeth Holdings Corporation | Adjuvant combination formulations |
| US7097837B2 (en) * | 2001-02-19 | 2006-08-29 | Pharmexa A/S | Synthetic vaccine agents |
| JP2002273199A (ja) * | 2001-03-15 | 2002-09-24 | Idemitsu Petrochem Co Ltd | ガス状流体の抜き出し方法 |
| US6906169B2 (en) * | 2001-05-25 | 2005-06-14 | United Biomedical, Inc. | Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide |
| MY144532A (en) * | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
| US20030185845A1 (en) * | 2001-11-16 | 2003-10-02 | Steen Klysner | Novel immunogenic mimetics of multimer proteins |
| EP1467751A2 (fr) | 2002-01-17 | 2004-10-20 | Pharmexa A/S | Antigene carcino-embryonnaire immunogene |
| AU2003208314A1 (en) * | 2002-03-11 | 2003-09-22 | Pharmexa A/S | Novel application of vaccination against tnf-alpha |
| AU2003256578A1 (en) * | 2002-07-17 | 2004-02-02 | Intellect Neurosciences, Inc. | Peptides and methods of screening immunogenic peptide vaccines against alzheimer's disease |
-
2002
- 2002-08-13 MY MYPI20023002A patent/MY144532A/en unknown
- 2002-08-20 US US10/223,809 patent/US20030157117A1/en not_active Abandoned
- 2002-08-20 PL PL369099A patent/PL215125B1/pl unknown
- 2002-08-20 KR KR1020107015762A patent/KR20100086520A/ko not_active Application Discontinuation
- 2002-08-20 KR KR10-2004-7002557A patent/KR20040044465A/ko not_active Application Discontinuation
- 2002-08-20 SI SI200230418T patent/SI1420815T1/sl unknown
- 2002-08-20 AU AU2002325199A patent/AU2002325199B2/en not_active Ceased
- 2002-08-20 HU HU0400669A patent/HUP0400669A3/hu not_active Application Discontinuation
- 2002-08-20 AR ARP020103113A patent/AR036270A1/es active IP Right Grant
- 2002-08-20 JP JP2003520770A patent/JP2004538332A/ja active Pending
- 2002-08-20 DE DE60213615.6T patent/DE60213615T3/de not_active Expired - Lifetime
- 2002-08-20 EP EP06000288A patent/EP1685847A1/fr not_active Ceased
- 2002-08-20 NZ NZ547224A patent/NZ547224A/en not_active IP Right Cessation
- 2002-08-20 IL IL15996402A patent/IL159964A0/xx unknown
- 2002-08-20 WO PCT/DK2002/000547 patent/WO2003015812A2/fr active Application Filing
- 2002-08-20 ES ES02758181.8T patent/ES2269749T5/es not_active Expired - Lifetime
- 2002-08-20 EA EA200400332A patent/EA007533B1/ru not_active IP Right Cessation
- 2002-08-20 RS YU13304A patent/RS51699B/sr unknown
- 2002-08-20 CN CN200910204496.3A patent/CN101675992B/zh not_active Expired - Fee Related
- 2002-08-20 BR BR0212047-0A patent/BR0212047A/pt not_active IP Right Cessation
- 2002-08-20 ME MEP-432/08A patent/MEP43208A/xx unknown
- 2002-08-20 CA CA2457140A patent/CA2457140C/fr not_active Expired - Fee Related
- 2002-08-20 AT AT02758181T patent/ATE334698T1/de active
- 2002-08-20 KR KR1020097013183A patent/KR101057488B1/ko active IP Right Grant
- 2002-08-20 NZ NZ530940A patent/NZ530940A/en unknown
- 2002-08-20 EP EP02758181.8A patent/EP1420815B2/fr not_active Expired - Lifetime
- 2002-08-20 PT PT02758181T patent/PT1420815E/pt unknown
- 2002-08-20 EP EP17194894.6A patent/EP3299029A1/fr not_active Withdrawn
- 2002-08-20 DK DK02758181T patent/DK1420815T3/da active
- 2002-08-20 EA EA200600974A patent/EA011610B1/ru not_active IP Right Cessation
- 2002-08-20 MX MXPA04001467A patent/MXPA04001467A/es active IP Right Grant
-
2004
- 2004-01-29 IS IS7133A patent/IS7133A/is unknown
- 2004-02-20 US US10/783,317 patent/US20050163744A1/en not_active Abandoned
- 2004-02-23 CO CO04015504A patent/CO5560581A2/es not_active Application Discontinuation
- 2004-03-05 HR HR20040218A patent/HRP20040218A2/hr not_active Application Discontinuation
- 2004-10-04 HK HK04107588A patent/HK1064934A1/xx not_active IP Right Cessation
-
2006
- 2006-10-26 CY CY20061101544T patent/CY1105737T1/el unknown
-
2007
- 2007-12-18 AU AU2007249087A patent/AU2007249087B2/en not_active Expired - Fee Related
- 2007-12-31 IL IL188506A patent/IL188506A/en not_active IP Right Cessation
-
2008
- 2008-12-19 US US12/339,841 patent/US8871212B2/en not_active Expired - Fee Related
-
2009
- 2009-06-12 JP JP2009141187A patent/JP5114455B2/ja not_active Expired - Fee Related
-
2010
- 2010-08-16 AU AU2010212381A patent/AU2010212381B2/en not_active Ceased
-
2012
- 2012-03-30 HR HRP20120283AA patent/HRP20120283A2/hr not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MEP43208A (en) | Beta-amyloid-analogue-t-cell epitop vaccine | |
| ME00183B (me) | Novi postupak za deregulaciju amiloida | |
| AU2018298422A1 (en) | Novel nucleic acid molecules | |
| PE20201264A1 (es) | Variantes de capsides de virus adenoasociados y metodos de uso de estas | |
| AR032597A1 (es) | Uso de antigenos del virus de la gripe inactivado, en la preparacion de vacunas de una sola dosis intranasal; metodo para la profilaxis de enfermedades o de infecciones gripales en pacientes; equipos que comprenden dichas vacunas en dosis unicas y metodo para fabricar vacunas para la gripe para apli | |
| NO20023829L (no) | Proteosom influensavaksine | |
| SE0202110D0 (sv) | Iscom preparation and use thereof | |
| UY27840A1 (es) | Vacunas | |
| BR112022016550A2 (pt) | Proteínas de ligação a flt3 e métodos de uso | |
| NO20054608L (no) | Influensavirusvaksine | |
| PT1206189E (pt) | Formulacoes para vacinas de rotavirus | |
| EA201391200A1 (ru) | Способы и композиции для вакцинации от staphylococcus aureus | |
| BR0211761A (pt) | depsipeptìdeos e processos para preparar os mesmos | |
| WO2021226267A3 (fr) | Compositions de virus adéno-associés compatibles entre espèces et leurs méthodes d'utilisation | |
| EA202191735A1 (ru) | Варианты альфа-галактозидазы человека | |
| NO20040431L (no) | Ny fremgangsmate for nedregulering av amyloid | |
| SE9903534D0 (sv) | Vaccin | |
| DE60126490D1 (de) | Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form | |
| AR027738A1 (es) | Composicion coadyuvante, composiciones de vacunas que incluyen dicha composicion coadyuvante; procedimiento de induccion de inmunorespuestas antigenicas enmamiferos y procedimiento de tratamiento donde se aplican dichas vacunas | |
| AR020852A1 (es) | Antigenos de vacuna de leptospira para la prevencion de leptospirosis | |
| CU23009A1 (es) | Preparaciones para potenciar la inmunogenicidad depreparaciones para potenciar la inmunogenicidad de antígenos poco inmunogénicos antígenos poco inmunogénicos | |
| YU87201A (sh) | Postupak za nishodnu regulaciju gdf-8 aktivnosti |